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Age biasIntroduction: Recruitment and retention are two of themost important factors in successfully running clinical tri-
als. Many trials encounter problems with both, causing delays or preventing study progress. These issues are
greater in older adults and patients with cancer.
Materials and methods:We assessed recruitment and retention in a large, multicentre, observational breast can-
cer study in older female patients (>70years,N=3440). Data collected by the AgeGap studywere used to assess
rates of, and reasons for, patients not being recruited or retained. Statistical analysis assessed the impact of age as
a predictor of recruitment and retention.
Results: Between February 2013 and June 2018, 6876 patients were screened and 3456were consented across 56
UnitedKingdom (UK)breast units. Reasons for non-recruitment included ineligibility, clinician issues, staffing re-
source issues, patients' lack of interest or time and trial burden. In comparisonwith the age demographics of pa-
tients with breast cancer in the UK, women aged 70–75 years were over-represented compared to older age
groups. Logistic regression demonstrated that older age significantly reduced the odds of consent (OR = 0.96,
CI: 0.938–0.982; p<0.001).Multivariate analysis showed that age (p< 0.001), markers of poor functional ability
(Eastern Cooperative Oncology Group Performance Status (p=0.011)) and instrumental activities of daily living
(p = 0.026) were significant predictors of withdrawal.
Discussion: This study has demonstrated that selection and attrition bias for age are apparent despite a range of
‘age friendly’ studydesignmeasures. Exploration of the underlying reasons for this and development ofmeasures
to address this should be the focus of further research.
© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Recruitment is the greatest practical problem in clinical trials. Less
than a third of publicly funded trials meet their recruitment targets
andoverhalf require anextension [1]. Recruitingolder patients is partic-
ularly challenging [2–6] but due to increased interest in representative
trial data [7–10], effective ways of recruiting older patients are needed.
This is increasingly important with aging global populations [11].. This is an open access article under
J. Morgan, et al., Age specific
.org/10.1016/j.jgo.2020.10.01Evidence suggests that, if approached, older patients are as likely
to participate in research as younger patients [12]. Older patients
have similar attitudes towards enrolment, stating motivators such
as altruism and hope for better treatments [13]. Despite this, older
patients with cancer are less likely to be offered a trial than younger
patients [4–6,13–15]. Difficulties in recruitment and retention of
older participants are often caused by strict eligibility criteria [3],
such as age and co-morbidity restrictions. Trialists have concerns
that older patients will have higher rates of treatment morbidity
and other causes of mortality, which may undermine any gains
from new treatments. Co-morbidity, concurrent medications andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
recruitment and retention to a large multicentre observational breast
5
A. Todd, C. Martin, J. Morgan et al. Journal of Geriatric Oncology xxx (2020) xxxorgan function impairment are often defined as exclusion criteria
which introduces age bias, as older patients have higher rates of
organ function impairment [16,17]. Other issues include lower levels
of literacy and numeracy, increased prevalence of dementia and al-
tered preferences for information provision (older patients are less
keen on online materials, complex percentages and graphic displays
[18]). Pragmatic trial design and minimally invasive recruitment
and data collection methods may help overcome this [3,9,10]. An-
other factor is health care professionals' attitudes to recruitment,
with clinicians wishing to avoid burdening older patients, concerns
about their fitness for trial interventions or feeling they are unable
to understand trial processes [12].
Attrition through patient withdrawal and loss to follow-up can also
have a negative effect on trial outcomes [19]. It is important that clinical
trials represent the populations treatments are designed to be used in
[7] and if attrition is weighted towards certain characteristics, attrition
bias may result [6,20]. In addition, findings from selected subpopula-
tions may not extrapolate to the real world [21,22].
Similar problems arise where recruited participants do not complete
the study which is a particular problem in patients with poor functional
status and dementia [23]. Patient health deterioration or patient choice
are often cited as reasons for discontinuation amongst older age groups
[24]. Older patientsmay also havemobility issues and struggle to attend
appointments. Lengthy follow-up schedules may also see patients be-
come too frail to maintain engagement.
Accurate recording of reasons for non-recruitment or retention,
which should be an integral component of good quality research [25],
is often inadequately reported. This limits our understanding of remedi-
able issues.
The Age Gap study was designed to recruit older patients with can-
cer [26]. It was a multicentre, observational study specifically recruiting
womenover the ageof 70with operable breast cancer. The trial assessed
the oncological impacts of breast cancer treatments when adjusted for
baseline variations in fitness, age and frailty using propensity score
matching. The trial was designed to enhance recruitment and retention
using a range of strategies suggested following the premature closure of
previous older age specific randomised trials due to poor recruitment
[27]. These included an observational design with propensity score
matched adjustment of baseline variables instead of randomisation,
use of enhanced, age appropriate, patient friendly trial literature, an in-
clusive recruitment strategy and varying levels of participation to suit
a patient's wishes.
The aim of this work was to determine the impact of age and health
status on recruitment and retention within the Age Gap study.2. Materials and methods
2.1. Aims
To determine the impact of age and health status on recruitment and
retention to a large prospective observational cohort study in a popula-
tion of olderwomenwith operable breast cancer (the Age Gap study co-
hort). In addition, the pattern of recruitment was compared to the age
demography of the wider UK population of women with breast cancer,
(derived from theUK Cancer Registrywebsite from2015 to 2017,which
was within the Age Gap study recruitment period from 2013 to 2018).
Details of the parent study are given below followed by details of this
planned subsidiary analysis.2.2. Regulatory approval
Ethics approval and research governance approval was obtained
(IRAS: 12 LO 1808).2
2.3. Study design
A prospective, multicentre, observational cohort study. Participation
at three levels: full participation, partial (no requirement to complete
quality-of-life assessments) or by proxy (minimal data collection for
women with dementia). Methodology for the main Age Gap study has
been previously published [26] and is briefly summarised below.
3. Sites
56 UK breast units (Table ST1).
Inclusion criteria:
1. Female, aged ≥70, with operable, invasive breast cancer with no
upper limit for age or health status.
2. Ability to provide informed consent or have a proxy give consent if
cognitively impaired.
Exclusion criteria:
1. Previous invasive breast cancer within five years
3.1. Screening data collection
At various stages of the recruitment process data were collected
about potential participants and why they did not progress to the next
stage of recruitment. Stages were defined as:
• Screening: Remote case review in multidisciplinary team meetings
(MDTs) or clinic
• Approach: Patient or caregiver contacted to assess initial interest
or not
• Eligibility Assessment: Detailed review of eligibility criteria
• Consent: Signed consent obtained.
At each stage details of patient age and ethnicity were recorded
along with whether they were approached about the study (and rea-
sons if not) and their interest in being involved in the study (and rea-
sons if not) using a specially developed case report form with closed
and open questions relating to participation or not, and reasons for
withdrawal.
3.2. Baseline data collection
The following data were collected at baseline:
• Charlson co-morbidity index, (CCI) [28]
• Activities of Daily Living (ADL) [29]
• Instrumental Activities of Daily Living (IADL) [30]
• Mini Mental State Examination (MMSE) [31]
• Eastern Cooperative Oncology Group Performance Status (ECOG-PS)
• Quality-of-life using a range of validated questionnaires [32,33].
• Tumour characteristics (grade, stage, receptor status)
• Cancer treatment details.
3.3. Follow-up and outcomes
Participantswerefollowed-upat6weeksand6,12,18and24months.
Pragmatic flexibility was allowed around visit timing: ±2weeks for the
6 week visit and ± 1 month for all other study visits. Data on patient
screening, recruitment and discontinuation from the study were col-
lected using a mixture of closed and open questions to determine rea-
sons for withdrawal. Discontinuation of participation was due to
death, voluntary withdrawal (patient/caregiver/Health Care Profes-
sional (HCP) decision and reason), involuntary withdrawal (inability
to comply and reason) and loss to follow-up. Reporting of methods
was compliant with STrengthening the Reporting of OBservational
studies in Epidemiology (STROBE) guidelines [34].
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strategies
The Age Gap study was designed to be ‘older patient friendly’ with
multiple features to enhance uptake and retention including:
• Observational cohort designwith propensity scorematching to adjust
for allocation bias rather than randomisation (previous randomised
trials, including those conducted by our group [27], in this age demo-
graphic have failed to recruit)
• No eligibility limits for comorbidity, frailty, or cognitive impairment.
Women with cognitive impairment were permitted to be consented
by proxy
• Flexible data collection time points
• Availability of telephone and postal follow-up to optimise for older
patients [3]
• Making elements of the trial optional such as quality-of-life form com-
pletion
• Extensive user involvement in trial design to optimise for older pa-
tients
• Direct follow-up limited to two years with longer-term follow-up via
the UK cancer registry.
3.5. Statistical analysis
Data analyses were performed using Excel and SPSS (Version 25).
P-values of <0.05 were considered significant. Medians and ranges
were used to report age due to the skewed age range [35]. Mann-
Whitney U tests were used to determine whether eligibility, consent
and withdrawal were associated with patient characteristics. Age
was categorised for the purposes of graphical displays but treated as
continuous in analyses.
Multivariable logistic regression was used to determine the effect
of age, participation level, ECOG-PS, cognitive capacity (MMSE,
categorised as normal/mild/moderate/severe impairment) and func-
tional capacity (ADL and IADL) on the likelihood of trial withdrawal.
For comparison of population sampling relative to the wider UK
population of women with breast cancer, age specific incidence data
from the Office for National Statistics (derived for 2015–2017) was
compared with age strata from the Age Gap study (2013–2018).
4. Results
4.1. Screened to recruited ratios and reasons for non-recruitment
The study was recruited between February 2013 and June 2018. Pa-
tient flows through screening and recruitment are illustrated in Fig. 1,
alongside reasons for not approaching (Table 1a), not formally assessing
eligibility (Table 1b), not consenting (Table 1c) and for discontinuation
(Table 2). The median age of women screened (77, range 70–102) was
younger than those not screened (79, range 69–101; p < 0.001, Fig. 2).
A total of 5593 women were approached about the study, of whom
3768 had a formal eligibility assessment (67%) and of these 3456
(92%) were consented. An additional sixteen patients were found to
be ineligible after consent when baseline data was collected, leaving
3440/3768 (91%) fully eligible women. The median age of women
consented was younger than those not consented (77, range 70–102
versus 79, range 70–95; p < 0.001) (Fig. 2).
Of the 3440 participants, 214 (6%) changed their level of participa-
tion. This included 209/214 (98%) participants who dropped from full
to partial participation and 5/214 (2%) who changed from partial to
data collection only. In total 487/3440 (14%) participants discontinued
the study for a variety of reasons (Table 2).
In terms of age and comorbidity related exclusions, co-morbidities
accounted for 35/1824 (1.9%) patients not screened, of these only 5/
1824 (0.3%) were due to frailty/age (Table 1b). Trial burden was3
reported by 247/1824 (13.5%) patients as the reason they were not in-
terested in the trial, 232/1824 (12.7%) stating the trial was too much
for them, 8/1824 (0.4%) reporting transport tissues and 7/1824 (0.4%)
due to their responsibilities as a caregiver. A lack of appropriate
consultees was reported for 10/1824 (0.5%) patients with cognitive im-
pairment. Decline of the trial was reported for 126/1824 (6.9%) patients
with 83/1824 (4.6%) being direct decline by patient and 43/1824 (2.4%)
where the patient could not be contacted. Of the patients that declined,
one patient did notwish to have their information reviewed and several
commented that the photo on the patient information sheet ‘looked too
old’ and they therefore didn't associate themselves with the trial's age
group (the photograph was subsequently changed). Five patients
(0.3%) were not happy to be assessed for the trial due to frailty or age,
4 of these reporting that they felt they were too old, representing only
0.3% of those not assessed for eligibility.
Of the patientswhowere assessed for eligibility and formally invited
to take part, 193/3768 (5%) did not consent, the most common reason
was trial burden reported by 58/193 (30.1%) patients (Table 1c) such
as completion of sometimes lengthy questionnaires. Lack of consultant
interest was cited as a reason for not assessing eligibility in 219 of
1824 (12%).
4.2. Trial discontinuation
A total of 487/3456 participants (14%) did not complete the
study, of these 226/487 (46.4%) died while on study, 120/487
(24.6%) withdrew themselves, 66/487 (13.6%) were lost to follow-
up, 10/487 (2.1%) participants were withdrawn by their carer and
65/487 (13.3%) participants did not complete for other reasons.
Only 9/487 (1.8%) participants withdrew due to comorbidities, al-
though a larger number stated they were withdrawing for health
reasons (41/487, 8.4%). Other reasons included finding the question-
naires too time consuming (11/487, 0.8%), or too difficult (4/487,
0.8%). Of the participants that were withdrawn by their caregiver
7/487 (1.4%) felt the participant could not continue due to health
problems. Only 1/487 (0.2%) had a caregiver who felt the study
was too difficult/intrusive. These are summarised in Table 2.
Patients who withdrew were generally older than women who did
not withdraw (median age of 80 (range 70–101) versus 76 (70–102);
p < 0.001, Fig. 3).
4.3. Population sampling for the Age Gap Study
A comparison of UK age-specific population distribution for breast
cancer, derived from the UKOffice for National Statistics, was compared
with the age-distribution of the Age Gap trial to determine whether
sampling was representative. This demonstrated that the younger age
groupswere overrepresented in this trial, whereas the older age groups
were under-represented (Fig. 4).
4.4. Logistic regression analysis of the impact of age on trial participation
Logistic regression showed age was a significant predictor of
whether patients were screened, assessed for eligibility, consented or
withdrawn (Tables 3 and 4).
This shows that a 90-year-old patient would have 0.44 odds ratio
(56% reduced odds) of being screened compared to a 70-year-old pa-
tient. For consent, a 90-year-old patient would have 0.44 odds ratio
(56% reduced odds) of being consented compared to a 70-year-old pa-
tient. For trial discontinuation, a 90-year-old patient having 6.14 odds
ratio of discontinuation compared to a 70-year-old patient.
4.5. Multivariate analysis
Multivariate analysis (Table 5) showed that, of the baseline charac-
teristics assessed, only age (p < 0.001), ECOG-PS (p = 0.011) and
Fig. 1. Flow Diagram showing patient numbers at each stage of trial recruitment and follow-up.
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Age increased the likelihood of withdrawal (Fig. 5), with an odds ratio
of 1.079 of being withdrawn per year of increasing age. Similarly, per-
formance status had a significant effect, with an odds ratio of 1.383
representing a 38.3% increase in odds of withdrawal with each reduc-
tion in level of functional ability. Increased IADL score was associated
with a reduction in the odds of being withdrawn from the study,
(odds ratio = 0.843) representing a 15.7% reduced odds of withdrawal
with each increasing point score.4
5. Discussion
The Age Gap trial has demonstrated that large-scale recruitment in
the older population is feasible but has confirmed a number of factors
affecting recruitment and discontinuation. Overall, 50.3% of patients
screened were recruited to the study which is in line with breast cancer
specific literature [36], as well as the general expectations for all trials.
Failure to achieve recruitment targets is common across multi centre,
publicly funded trials [1]. As with over half of publicly funded trials,
Table 1
Reasons patient were not screened for eligibility, not eligibility assessed or consented.
Reason patient not screened Count (%) [N = 1169]
Previous breast cancer and therefore ineligible 109 (9.3)
Other 1060 (90.7)
Already started treatment 279 (23.9)
Clinical decision not to approach 109 (9.3)
Co-morbidities 35 (3.0)
Ineligible (other than started treatment) 354 (30.3)
Research Staffing/Resource issues 115 (9.8)
Treatment at another hospital/declined treatment 47 (4.0)
Contact issues 15 (1.3)
Could not be contacted 9 (0.8)
Did not attend appointment 6 (0.5)
Lack of consultee for patient with dementia 34 (2.9)
Language barrier 12 (1.0)
Not interested 12 (1.0)
Trial enrolment would be ‘Too much’ for them 33 (2.8)
Patient died 2 (0.2)
No reason 5 (0.4)
Unable to categorise 8 (0.7)
Reason patient not assessed for eligibility Count (%) [N = 1824]
Consultee not interested 219 (12.0)
Lack of Time 195 (10.7)
Not interested in questionnaires 171 (9.4)
Not specified 448 (24.6)
Other: 789 (43.3)
Already started treatment 176 (9.6)
Co-morbidities: 35 (1.9)
Visual impairment 4 (0.2)
Frailty or ‘Age’ 5 (0.3)
Other co-morbidities 26 (1.4)
Ineligible (other than started treatment) 60 (3.3)
Staffing/Resource issue 21 (1.2)
Treatment at another hospital/declined treatment 92 (5.0)
Private care 8 (0.4)
Treatment at another hospital 74 (4.1)
GP care only 1 (0.1)
No treatment/follow-up 9 (0.5)
Declined 126 (6.9)
Unable to contact patient 43 (2.4)
Patient declined 83 (4.6)
Trial Burden 247 (13.5)
Too much 232 (12.7)
Transport issues 8 (0.4)
Acts as a carer 7 (0.4)
Could not be consented due to lack of consultee 10 (0.5)
Could not be consented due to language barrier 4 (0.2)
Unable to categorise 20 (1.1)
Reason patient not consented,
(where given, more than one reason possible)
Count (%) [N = 193]
Consultee not interested 15 (7.8)
Lack of Time 27 (14.0)
Not interested in questionnaires 18 (9.3)
Not specified 33 (17.1)
Other: 100 (51.8)
Trial burden 58 (30.1)
Too much 55 (28.5)
Transport 3 (1.6)
Already started treatment 14 (7.3)
Staffing/Resource issue 8 (4.1)
Not Interested in trial 10 (5.2)
Treatment at another hospital/declined treatment 3 (1.6)
Private hospital 2 (1.0)
Other hospital 1 (0.5)
Co-morbidities 2 (1.0)
More time needed to consider trial 1 (0.5)
Language barrier 1 (0.5)
Did not attend appointment 1 (0.5)
Unable to categorise 2 (1.0)
Table 2
Reasons patients did not complete the study.
Reason for discontinuation Count (%) [N = 487]
Patient died 226 (46.4)
Breast cancer recorded as primary cause 91 (19)
Breast cancer not recorded as primary cause 123 (25)
Cause of death uncertain 12 (2)
Participant choice 113 (23)
No longer feels able to take part due to health reasons 41 (8.4)
Questionnaires too difficult 4 (0.8)
Questionnaires too time consuming 11 (2.3)
Other 25 (5.1)
No reason given 32 (6.6)
Lost to follow-up 66 (14)
Carer choice 10 (2.1)
No longer feels able to take part due to health reasons 7 (1.4)
Carer feels the study is too difficult/intrusive 1 (0.2)
Other 2 (0.4)
Other⁎ 65 (13)
Ineligible 20 (4.1)
Co-morbidities 9 (1.8)
Staffing/Resource issue 24 (4.9)
Patient moved 12 (2.5)
⁎ Initially 83 ‘other’ recordswere identified however 18were categorised into the given
options.
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the Age Gap trial required an extension due to slower than anticipated
recruitment.
The Age Gap trial made efforts to counter the issues that reduce re-
cruitment in the older patient (listed above). Our own experienceswith
the Endocrine or Surgical Therapy for Elderly womEnwith Mammary
cancer randomised trial (ESTEEM, surgery versus PET) and the Adjuvant
Cytotoxic Chemotherapy in Older Women randomised trial (ACTION,
chemotherapy in olderwomen)providedavaluable insight into thebar-
riers and facilitators of recruitment and informed the design of Age Gap
[27]. Trialdesignavoided restrictiveeligibility criteria,whichreduced re-
cruitment rates in the older patient [3], and consequently few patients
were excluded due to this. Notmeeting eligibility criteria accounted for
only 30.3% of those screened being ineligible, suggesting that a range of
otherpotentiallyunknownissuesinfluencedrecruitmentandpotentially
introducedbias. Comorbiditiesarea commonreason forolderpatients to
be excluded from clinical trials [12]. Age Gap deliberately wished to re-
cruit the widest range of fitness levels possible to permit propensity
score matching for health status and as a result, comorbidity only
accounted for 3% of those screened not being assessed for eligibility.
Retention in older patients is challenging, especially in longer trials,
however participant choice only accounted for approximately one in
twowithdrawals (45.8%). The length of follow-up affects attrition, espe-
cially in older patients [37], howeverwe have shown that it is feasible to
follow patients up for two years with only a 13.1% attrition rate due to
the low trial burden and pragmatic approach to follow-up. To keep bur-
densome direct follow-up to a minimum, longer-term follow-up was
via the cancer registry, which increased follow-up duration with mini-
mal cost and patient burden.
All analyses demonstrated that age was a significant predictor of
whether patients were screened, assessed for eligibility, consented or
withdrawn. Increasing age resulted in patients being less likely to be
screened, assessed for eligibility or consented and an increasing likeli-
hood of being withdrawn. As risk of death increases with age [11], this
will have an effect on withdrawals.
Representation of different age groups in line with age specific can-
cer incidence in England also confirmed skewed age specific recruit-
ment, with only half the expected patients over age 90 screened
Fig. 2. Graph to illustrate the number of patients screened for entry (total number is patients presenting at site) or consented (total number is patients who are eligible) by age category.
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subject frail and potentially vulnerable patients to the burden of trial
participation. Staff reticence is shown in the age differential in screeningFig. 3. Graph to illustrate the percentage of patients w
6
and eligibility assessmentwhere patients and carers have not even been
approached at this stage of the recruitment process. Reduced trial repre-
sentation at the extremes of age may have an impact on trial analysis inho discontinued the study for each age category.
Fig. 4.Graph of Incidence of breast cancer in the over 70 age group (CRUKpercentage data derived from theUKOffice for National Statistics) compared to Age Gap screened and consented
percentages of corresponding age groups.
Table 3
Univariate logistic regression of age as a predictor for patients being screened, assessed for eligibility, consented and discontinued from the study.
Independent Variable Sample size Dependent Variable Odds ratio 95% CI p-value
Age 6876 Screened for eligibility 0.960 0.951–0.969 <0.001
3768 Eligibility assessment 0.966 0.958–0.975 <0.001
3456 Consented to study 0.960 0.938–0.982 <0.001
487 Discontinued study 1.095 1.095–1.112 <0.001
Table 4
Results of univariate logistic regression: Anassessment of age group as a predic-
tor for patients being screened, assessed for eligibility, consented orwithdrawn.
Independent
Variable
Dependent
Variable
Age
Category
Odds
ratio
95% CI p-value
Age category Screened
(N = 6757)
70–75 1.0 N/A <0.001
75–80 1.204 1.008–1.439 0.400
80–85 0.820 0.688–0.979 0.028
85–90 0.678 0.555–0.827 <0.001
90+ 0.383 0.303–0.484 <0.001
Eligibility
(N = 5590)
70–75 1.0 N/A <0.001
75–80 0.943 0.814–1.092 0.431
80–85 0.773 0.661–0.904 <0.001
85–90 0.537 0.448–0.644 <0.001
90+ 0.543 0.420–0.700 <0.001
Consented
(N = 3647)
70–75 1.0 N/A 0.007
75–80 0.808 0.545–1.197 0.288
80–85 0.515 0.348–0.763 <0.001
85–90 0.524 0.324–0.846 0.008
90+ 0.750 0.350–1.610 0.461
Withdrawn
(N = 3454)
70–75 1.0 N/A <0.001
75–80 1.492 1.126–1.976 0.005
80–85 2.929 2.219–3.866 <0.001
85–90 3.764 2.734–5.182 <0.001
90+ 6.254 4.206–9.301 <0.001
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by proactively identifyingwomen in this older group to compensate for
this [24], to have quota for each age range, or to adjust at the analysis
stage by allocating greater weight to data from under-represented sub-
groups as a sensitivity analysis [39]. None of these approaches are likely
to fully correct for volunteer bias (either in respect to age or to other
characteristics), but nevertheless a partial adjustment is arguably better
than none at all [39]. Lastly, steps to minimise the burden to patients
and to embed researchwithin routine care canmake trialsmore appeal-
ing to patients whomay otherwise be too “frail” to participate [10]. The
design of the trial already included an ‘Age Gap Lite’ option, where par-
ticipants could elect not to complete trial questionnaires and a proxy
arm for patients lacking cognitive capacity where simple data collection
only was an option to help address this issue.
Age bias from health care professionals (both doctors and nurses) is
one factor which trial design struggles to mitigate for. Health care pro-
fessionals act as gatekeepers and may create a barrier to recruitment
[12]. Health care professional decisions can account for 50–80% of pa-
tients not being offered trial participation [37]. Whilst this may not be
purely age bias, the close link between age, fitness, frailty and cognitive
status makes this difficult to tease apart. Rates of health care profes-
sional exclusion in Age Gap were much lower, at only 9.3% of those
not screened. Data suggests that clinicians assume that older patients
are not interested in the trials [12]. However, only 0.2% of those not
assessed for eligibility and 0.5% of those not consented stated their age7
Table 5
Results of multivariate analysis: An assessment of health status and age predictors of
patients being withdrawn.
Independent
Variable
Dependent
Variable
N Odds
ratio
95% CI p-value
Withdrawn Age 3454 1.079 1.054–1.104 <0.001
Participation
Level
3456 0.768 0.547–1.078 0.128
MMSE 2291 1.274 0.981–1.653 0.069
ECOG-PS 3232 1.383 1.076–1.776 0.011
ADL 3037 1.073 0.970–1.188 0.170
IADL 2984 0.843 0.726–0.980 0.026
MMSE: Mini Mental State Examination, ECOG-PS: European Cooperative Oncology
Group-Performance Status, ADL: Activities of Daily Living, IADL: Instrumental Activities
of Daily Living.
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literature that the older population are generally happy to be involved
in research [13]. Carer reticence, due to a wish to protect a vulnerable
relative,may also be a factor. There are also social factors thatmay influ-
ence participation and other as yet unknown factors that justify further
research into this issue.
Further to clinician and eligibility barriers, patient and funding
barriers can also have an effect on recruitment and retention. The
consequence of funding barriers were represented in this study by
the number of potentially eligible patients that were not screened
(9.8%), assessed for eligibility (1.2%) or consented (4.1%) due to
staffing or resource issues (such as lack of availability of research
nurses which was an issue in some centres). These issues unfairly
disadvantage older patients who are less inclined to attend additional
study specific visits due to co-morbidities and transport issues [12,37]
so need to be seen during their clinic visit, which requires research
staff flexibility.
It has been suggested that older patients are less informed about tri-
als and this is a reasonwhy recruitment rates are lower in the older pop-
ulation [40]. Although basic information such as years of schooling and
overall cognition was collected through the MMSE questionnaire,Fig. 5. Predicted risk of withdrawal by
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specific information on health literacy especially in relation to trials,
was not collected. Several campaigns have shown that it is possible to
increase clinical trial awareness [41], and these methods could be
used in the older population to potentially increase recruitment rates.
Some inferences can be made about patient perceptions of the trial
from overall recruitment numbers and the reasons patients provided
for not being interested in the trial, however more detailed data collec-
tion forms and in-depth qualitative methods could provide more infor-
mation in future trials.
It has been suggested that cognitive and performance status data
are collected routinely to allow easier comparisons between studies
[24]. This is due to poor ECOG-PS and high symptom burden being
predictors of drop-out. Indeed, ECOG-PS was a significant predictor
of withdrawal in this study. This could be useful for future studies to
produce a more accurate projection of anticipated attrition, allow
sample size calculations and recruitment targets to be adjusted for
this. It is also important to ensure that inclusion and exclusion criteria
closely reflect the clinical population demographics and do not restrict
age and performance status unless absolutely necessary. One option to
address this is to conduct trials specifically recruiting in this older age
group, although as we have shown, skewed recruitment still occurs, so
this solution is not perfect.
Acceptable trial design can be aided by patient and public involve-
ment (PPI) in trial conduct and design which increases recruitment, es-
pecially when PPI members have personal experience of the disease
[42]. The Age Gap PPI group fed into the design of the trial to ensure de-
sign and materials were acceptable to patients. Making patients aware
that other patients in their age group have helped to design and run
the trial may also be an incentive for participation.5.1. Generalisability and implications for practice
The gradual under-representation of patients as they get older re-
duces the generalisability of the trial. Methods tomake trial participants
more representative need to be developed urgently.age plus 95% confidence intervals.
A. Todd, C. Martin, J. Morgan et al. Journal of Geriatric Oncology xxx (2020) xxx6. Conclusion
The Age Gap trial has shown that it is feasible to recruit and retain
older patients on a large scale where the study scope and design is ap-
propriate. It has highlighted that there are still a large number of poten-
tial threats to representative recruitment and retention and further
progress is needed. This project highlights some issues that may be ad-
justed for at trial design stage.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.jgo.2020.10.015.
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